Investigational drug · Phase 2
Brogidirsen
Also called: NS-089, NCNP-02
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Duchenne Muscular Dystrophy, Exon 44, DMD.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Brogidirsen"
First trial start
2021
Jun 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Brogidirsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Duchenne Muscular Dystrophy
- Exon 44
- DMD
- Duchenne Muscular Dystrophy (DMD)
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Brogidirsen" as an intervention, largest first.
- NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)Active, not recruiting
NS Pharma, Inc.Industry
NCT05996003 · 20 participants (planned) · Start Feb 22, 2024 · Primary completion Feb 26, 2027
Drug: NS-089/NCNP-02 · For: Duchenne Muscular Dystrophy; Exon 44; DMD
Sites: Aurora, Colorado; Atlanta, Georgia; Chicago, Illinois · 29 sites in all
- A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyEnrolling by invitation
NS Pharma, Inc.Industry
NCT07943598 · 20 participants (planned) · Start Dec 16, 2026 · Primary completion Sep 3, 2029
Drug: Brogidirsen · For: Duchenne Muscular Dystrophy; Exon 44; DMD
Sites: Aurora, Colorado; Cincinnati, Ohio; Richmond, Virginia · 17 sites in all
- Extension Study of NS-089/NCNP-02 in DMDActive, not recruiting
Nippon Shinyaku Co., Ltd.Industry
NCT05135663 · 6 participants · Start Jun 23, 2021 · Primary completion Apr 30, 2027
Drug: NS-089/NCNP-02; NS-089/NCNP-02 · For: Duchenne Muscular Dystrophy (DMD)
Sites: Kagoshima, Japan; Tokyo, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy.
Tang A, Yokota T · Genes (Basel) 2025
- Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy.
Komaki H, Takeshita E, Kunitake K, et al. · Cell Rep Med 2025
- Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide.
Watanabe N, Tone Y, Nagata T, et al. · Mol Ther Nucleic Acids 2023
- Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial.
Ishizuka T, Komaki H, Asahina Y, et al. · Neuropsychopharmacol Rep 2023
- Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy.
Wilton-Clark H, Yokota T · Pharmaceutics 2023
- Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
Echigoya Y, Yokota T · Methods Mol Biol 2023
Also in development for Duchenne Muscular Dystrophy
- AOC 1044Phase 33 trials
Avidity Biosciences, Inc. · DMD, Duchenne Muscular Dystrophy, Exon 44
- DeramiocelCAP-1002, Allogeneic Cardiosphere-Derived CellsPhase 32 trials
Capricor Inc. · Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic
- SGT-003Phase 32 trials
Solid Biosciences Inc. · Duchenne Muscular Dystrophy, Advanced Solid Tumor
- SevasemtenPhase 24 trials
Edgewise Therapeutics, Inc. · Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
- BMN 351Phase 22 trials
BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
- WVE-N531Phase 22 trials
Wave Life Sciences USA, Inc. · Duchenne Muscular Dystrophy
- NS-050NCNP-03Phase 21 trial
NS Pharma, Inc. · Duchenne Muscular Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.